The Canadian government has responded to Eli Lilly’s complaint that recent decisions to invalidate two Lilly patents violated the North American Free Trade Agreement, saying that Lilly’s challenge is “wholly without merit”, and should be dismissed.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
17 September 2013 Eli Lilly has filed a NOA against the Canadian government, alleging recent decisions that invalidated patents covering its Zyprexa and Strattera drugs were in breach of NAFTA.
17 September 2013 Eli Lilly has filed a NOA against the Canadian government, alleging recent decisions that invalidated patents covering its Zyprexa and Strattera drugs were in breach of NAFTA.
17 September 2013 Eli Lilly has filed a NOA against the Canadian government, alleging recent decisions that invalidated patents covering its Zyprexa and Strattera drugs were in breach of NAFTA.